Control of hepatic T cell responses in biliary atresia

胆道闭锁中肝 T 细胞反应的控制

基本信息

  • 批准号:
    10133058
  • 负责人:
  • 金额:
    $ 41.29万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-08-15 至 2023-04-30
  • 项目状态:
    已结题

项目摘要

Project Summary/ Abstract Biliary atresia (BA) refers to idiopathic obliteration of the biliary tree in neonates. Unfortunately, up to 50% of infants who undergo attempts at surgical restoration of bile flow by hepatoportoenterostomy (HPE) remain cholestatic and rapidly progress to end-stage liver disease. Potential therapeutic targets include hepatic NK, CD8 and Th17-lymphocytes which have been identified as drivers of inflammatory ductal obstruction and progressive injury of the intrahepatic biliary epithelium. Our group has reported that regulatory T cells (Tregs) are able to restrain hepatic lymphocyte responses protecting from bile duct injury and initiation of liver fibrosis. Therefore, we explored the mechanisms controlling Treg/Th17 homeostasis under cholestatic conditions recapitulating progressive BA. Our preliminary findings demonstrate that conjugated bile acids (CBA) repress expression of the Treg- transcription factor Foxp3 and inhibit Treg-function in vitro. In the Mdr2-/- mouse model of “toxic bile” induced progressive cholestasis, inhibition of intestinal bile acid reuptake resulted in dramatic reduction in serum bile acid concentration which shifted cytokine production by Kupffer cells accompanied by rapid hepatic expansion of Tregs. In rotavirus induced murine BA, treatment with Fxr agonists induced expression of Il-10 in hepatic mononuclear cells, expanded Tregs, and attenuated the BA phenotype. We hypothesize that bile acids are epigenetic modifiers that control Treg homeostasis and determine the inflammatory microenvironment in the liver through activation of the bile acid receptors Tgr5 and Fxr. We will test this hypothesis by investigating the molecular mechanisms mediating bile acid induced silencing of Foxp3 in vitro and by deleting candidate molecular targets for CBA in CD4 lymphocytes in mice with acute or chronic cholestasis (Aim 1). In Aim 2, the effects of activation of Tgr5 and Fxr on regulation of macrophage derived cytokine production and Treg homeostasis, and on the fibrosing cholangiopathy phenotype will be studied in bone marrow transplant experiments and in conditional bile acid receptor knockout mice. For validation in human disease, we will investigate whether hepatic T lymphocyte responses are associated with distinct clinical phenotypes by analyzing liver RNAseq and clinical data and performing immunofluorescence and image analysis on archived liver biopsies from an inception cohort of 203 patients with BA followed by the multicenter Childhood Liver Disease Research Network (Aim 3). In preliminary studies we generated a gene list of Th17 associated genes from in vitro polarized neonatal Th17 lymphocytes. Hierarchical cluster analysis of these experimentally derived Th17 candidate genes in liver RNAseq data from 137 patients with BA revealed clusters of patients with similar gene expression profile. Serum conjugated bilirubin levels differed between these clusters, supporting our hypothesis. Future studies will interrogate segregation of clusters defined by integrated RNAseq- and immunofluorescence - based enumeration of liver infiltrating T cells with BA phenotype and HPE outcome.
项目摘要/摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Alexander Miethke其他文献

Alexander Miethke的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Alexander Miethke', 18)}}的其他基金

The role of regulatory T cells in biliary atresia
调节性T细胞在胆道闭锁中的作用
  • 批准号:
    8529520
  • 财政年份:
    2012
  • 资助金额:
    $ 41.29万
  • 项目类别:
The role of regulatory T cells in biliary atresia
调节性T细胞在胆道闭锁中的作用
  • 批准号:
    8400215
  • 财政年份:
    2012
  • 资助金额:
    $ 41.29万
  • 项目类别:
The role of regulatory T cells in biliary atresia
调节性T细胞在胆道闭锁中的作用
  • 批准号:
    8893971
  • 财政年份:
    2012
  • 资助金额:
    $ 41.29万
  • 项目类别:
Control of hepatic T cell responses in biliary atresia
胆道闭锁中肝 T 细胞反应的控制
  • 批准号:
    9816284
  • 财政年份:
    2012
  • 资助金额:
    $ 41.29万
  • 项目类别:
The role of regulatory T cells in biliary atresia
调节性T细胞在胆道闭锁中的作用
  • 批准号:
    9096771
  • 财政年份:
    2012
  • 资助金额:
    $ 41.29万
  • 项目类别:
Control of hepatic T cell responses in biliary atresia
胆道闭锁中肝 T 细胞反应的控制
  • 批准号:
    10378600
  • 财政年份:
    2012
  • 资助金额:
    $ 41.29万
  • 项目类别:
Enrichment Program
强化计划
  • 批准号:
    10442032
  • 财政年份:
    2007
  • 资助金额:
    $ 41.29万
  • 项目类别:
Enrichment Program
强化计划
  • 批准号:
    10620732
  • 财政年份:
    2007
  • 资助金额:
    $ 41.29万
  • 项目类别:
Clinical Center for Cholestatic Liver Disease in Children
儿童胆汁淤积性肝病临床中心
  • 批准号:
    10631943
  • 财政年份:
    2002
  • 资助金额:
    $ 41.29万
  • 项目类别:
Clinical Center for Cholestatic Liver Disease in Children
儿童胆汁淤积性肝病临床中心
  • 批准号:
    10414932
  • 财政年份:
    2002
  • 资助金额:
    $ 41.29万
  • 项目类别:

相似海外基金

ACUTE OTITIS MEDIA--ADJUVANT THERAPY TO IMPROVE OUTCOME
急性中耳炎——改善疗效的辅助治疗
  • 批准号:
    6566709
  • 财政年份:
    2001
  • 资助金额:
    $ 41.29万
  • 项目类别:
ACUTE OTITIS MEDIA--ADJUVANT THERAPY TO IMPROVE OUTCOME
急性中耳炎——改善疗效的辅助治疗
  • 批准号:
    6413648
  • 财政年份:
    2000
  • 资助金额:
    $ 41.29万
  • 项目类别:
ACUTE OTITIS MEDIA--ADJUVANT THERAPY TO IMPROVE OUTCOME
急性中耳炎——改善疗效的辅助治疗
  • 批准号:
    6305272
  • 财政年份:
    1999
  • 资助金额:
    $ 41.29万
  • 项目类别:
ACUTE OTITIS MEDIA--ADJUVANT THERAPY TO IMPROVE OUTCOME
急性中耳炎——改善疗效的辅助治疗
  • 批准号:
    6115194
  • 财政年份:
    1998
  • 资助金额:
    $ 41.29万
  • 项目类别:
ACUTE OTITIS MEDIA--ADJUVANT THERAPY TO IMPROVE OUTCOME
急性中耳炎——改善疗效的辅助治疗
  • 批准号:
    6276403
  • 财政年份:
    1997
  • 资助金额:
    $ 41.29万
  • 项目类别:
ACUTE OTITIS MEDIA--ADJUVANT THERAPY TO IMPROVE OUTCOME
急性中耳炎——改善疗效的辅助治疗
  • 批准号:
    6276429
  • 财政年份:
    1997
  • 资助金额:
    $ 41.29万
  • 项目类别:
ACUTE OTITIS MEDIA--ADJUVANT THERAPY TO IMPROVE OUTCOME
急性中耳炎——改善疗效的辅助治疗
  • 批准号:
    6246326
  • 财政年份:
    1997
  • 资助金额:
    $ 41.29万
  • 项目类别:
ACUTE OTITIS MEDIA--ADJUVANT THERAPY TO IMPROVE OUTCOME
急性中耳炎——改善疗效的辅助治疗
  • 批准号:
    2128074
  • 财政年份:
    1995
  • 资助金额:
    $ 41.29万
  • 项目类别:
ACUTE OTITIS MEDIA--ADJUVANT THERAPY TO IMPROVE OUTCOME
急性中耳炎——改善疗效的辅助治疗
  • 批准号:
    2128073
  • 财政年份:
    1995
  • 资助金额:
    $ 41.29万
  • 项目类别:
ACUTE OTITIS MEDIA--ADJUVANT THERAPY TO IMPROVE OUTCOME
急性中耳炎——改善疗效的辅助治疗
  • 批准号:
    2700951
  • 财政年份:
    1995
  • 资助金额:
    $ 41.29万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了